EQUALISE Type B: Clinical Results of Itolizumab, a Novel Anti-CD6 Therapy, in Subjects with Lupus Nephritis SA-PO875

Authors

Nelson Kopyt DO, FASN, FACP, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2023

Volume

34

Issue

11

First Page

971

Last Page

971

Published In/Presented At

Kalunian, Kenneth1; Parameswaran, Sreejith2; Levin, Robert W.3; Kopyt, Nelson P.4; Connelly, Stephen5; Sun, Eugene5; Kim, Catherine5; Fung, Maple M.5; Rathi, Manish6. EQUALISE Type B: Clinical Results of Itolizumab, a Novel Anti-CD6 Therapy, in Subjects with Lupus Nephritis: SA-PO875. Journal of the American Society of Nephrology 34(11S):p 971, November 2023. | DOI: 10.1681/ASN.20233411S1971a

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article